Literature DB >> 10913390

Assessment of the relationship between antimicrobial usage and susceptibility: differences between the hospital and specific patient-care areas.

R L White1, L V Friedrich, L B Mihm, J A Bosso.   

Abstract

Current evidence suggests that controlling antibiotic resistance requires the monitoring of both susceptibility trends and antimicrobial usage within specific patient-care areas of the hospital. To assess the differences between antimicrobial usage-versus-susceptibility relationships found in the hospital and those relationships found in specific patient-care areas, susceptibility and antimicrobial usage data collected over a 5-year period (1992-1996) at the Medical University of South Carolina were analyzed. For each area, the relationship between drug use and susceptibility was analyzed for 8 gram-negative organisms with respect to 19 different agents and for 3 staphylococci with respect to 10 agents with use of simple linear regression. The relationships found in the hospital had a poorer overall agreement with the relationships found in the intensive care units (ICUs; <20%) than they did with the relationships found in the non-ICUs ( approximately 65%). Surveillance should include both susceptibility and drug usage patterns in individual areas within an institution.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10913390     DOI: 10.1086/313916

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  9 in total

1.  Relationship between glycopeptide use and decreased susceptibility to teicoplanin in isolates of coagulase-negative staphylococci.

Authors:  M Bertin; A Muller; X Bertrand; C Cornette; M Thouverez; D Talon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-04-27       Impact factor: 3.267

2.  Complicated community-acquired soft tissue infection by MRSA from porcine origin.

Authors:  Ph Declercq; D Petré; B Gordts; A Voss
Journal:  Infection       Date:  2007-10-31       Impact factor: 3.553

3.  Time series analysis as a tool to predict the impact of antimicrobial restriction in antibiotic stewardship programs using the example of multidrug-resistant Pseudomonas aeruginosa.

Authors:  Matthias Willmann; Matthias Marschal; Florian Hölzl; Klaus Schröppel; Ingo B Autenrieth; Silke Peter
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

4.  Comparison of Hospitalwide and Custom Antibiograms for Clinical Isolates of Pseudomonas aeruginosa.

Authors:  John A Bosso; Adam Sieg; Patrick D Mauldin
Journal:  Hosp Pharm       Date:  2013-04

5.  Dynamic Changes of Staphylococcus aureus Susceptibility to Vancomycin, Teicoplanin, and Linezolid in a Central Teaching Hospital in Shanghai, China, 2008-2018.

Authors:  Ying Jian; Huiying Lv; Junlan Liu; Qian Huang; Yao Liu; Qian Liu; Min Li
Journal:  Front Microbiol       Date:  2020-05-12       Impact factor: 5.640

6.  Changes in the pattern of hospital intravenous antimicrobial use in Saudi Arabia, 2006-2008.

Authors:  Jaffar A Al-Tawfiq
Journal:  Ann Saudi Med       Date:  2012 Sep-Oct       Impact factor: 1.526

7.  Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan.

Authors:  Po-Ren Hsueh; Wen-Hwei Chen; Kwen-Tay Luh
Journal:  Int J Antimicrob Agents       Date:  2005-11-08       Impact factor: 5.283

8.  Antibiotic consumption and healthcare-associated infections caused by multidrug-resistant gram-negative bacilli at a large medical center in Taiwan from 2002 to 2009: implicating the importance of antibiotic stewardship.

Authors:  I-Ling Chen; Chen-Hsiang Lee; Li-Hsiang Su; Ya-Feng Tang; Shun-Jen Chang; Jien-Wei Liu
Journal:  PLoS One       Date:  2013-05-30       Impact factor: 3.240

9.  Lessons Learned from Surveillance of Antimicrobial Susceptibilities of Pseudomonas aeruginosa at a Large Academic Medical Center.

Authors:  Brett H Heintz; Jenana Halilovic
Journal:  Pharmaceuticals (Basel)       Date:  2010-04-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.